Zeke Capital Advisors’s Novartis NVS Stock Holding History

Zeke Capital Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$4.56M	Sell	50,236 -9,374	-16%	-$790K	0.3%	41
2022 Q3	$4.53M	Sell	59,610 -28	-0%	-$2.32K	0.33%	41
2022 Q2	$5.04M	Buy	59,638 +5,868	+11%	+$515K	0.34%	39
2022 Q1	$4.72M	Buy	53,770 +5,641	+12%	+$488K	0.24%	48
2021 Q4	$4.21M	Buy	48,129 +4,752	+11%	+$395K	0.25%	40
2021 Q3	$3.55M	Sell	43,377 -658	-1%	-$59.2K	0.2%	47
2021 Q2	$4.02M	Buy	44,035 +472	+1%	+$42K	0.25%	50
2021 Q1	$3.72M	Hold	43,563	–	–	0.26%	50
2020 Q4	$4.11M	Buy	43,563 +28,735	+194%	+$2.51M	0.34%	40
2020 Q3	$1.29M	Sell	14,828 -155	-1%	-$13.4K	0.15%	50
2020 Q2	$1.31M	Sell	14,983 -1,369	-8%	-$118K	0.25%	45
2020 Q1	$1.35M	Sell	16,352 -33,109	-67%	-$2.95M	0.38%	34
2019 Q4	$4.68M	Buy	49,461 +473	+1%	+$42.4K	0.39%	48
2019 Q3	$4.26M	Buy	48,988 +391	+0.8%	+$35.1K	0.38%	55
2019 Q2	$4.44M	Sell	48,597 -5,019	-9%	-$425K	0.42%	58
2019 Q1	$4.62M	Buy	53,616 +1,024	+2%	+$82.2K	0.43%	48
2018 Q4	$4.04M	Sell	52,592 -3,527	-6%	-$275K	0.39%	51
2018 Q3	$4.33M	Buy	56,119 +1,572	+3%	+$116K	0.35%	52
2018 Q2	$3.69M	Buy	54,547 +49,583	+999%	+$3.42M	0.34%	55
2018 Q1	$360K	Sell	4,964 -186	-4%	-$14.2K	0.03%	405
2017 Q4	$387K	Buy	5,150 +2,167	+73%	+$164K	0.04%	339
2017 Q3	$229K	Hold	2,983	–	–	0.03%	387
2017 Q2	$223K	Sell	2,983 -670	-18%	-$47.5K	0.04%	257
2017 Q1	$243K	Buy	+3,653	New	+$243K	0.05%	218

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Zeke Capital Advisors's NVS Position: Q4 2022 in Review

Zeke Capital Advisors reduced its Novartis (NVS) stake by 16% in Q4 2022, selling an estimated $790K and leaving 50,236 shares worth $4.56M. The position accounts for 0.3% of the portfolio, ranked #41.

Zeke Capital Advisors first reported a position in NVS in Q1 2017 and has held it in 24 quarters since. The position peaked at $5.04M in Q2 2022. 1,182 funds tracked by Wall St. Rank hold NVS as of Q4 2022.

Zeke Capital Advisors held 50,236 shares of Novartis worth $4.56M as of Q4 2022.
Zeke Capital Advisors sold 9,374 Novartis shares in Q4 2022, an estimated $790K.
Novartis made up 0.3% of Zeke Capital Advisors's portfolio in Q4 2022, its #41 holding.
Zeke Capital Advisors first reported a position in Novartis in Q1 2017 and has held it in 24 quarters since.
Zeke Capital Advisors's Novartis position peaked at $5.04M in Q2 2022.
1,182 funds tracked by Wall St. Rank held Novartis as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.